In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Akino Mercy Charles Solomon *Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Carson D Poltorack *Cell and Molecular Biology Graduate Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Sharan VenkateshDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Keren M AdlerDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Maggie R RobertsonDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Dingwen TaoDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Nelson F FreeburgDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Funding
U.S. Department of Defense (United States Department of Defense) W81XWH2210008U.S. Department of Defense (United States Department of Defense) W81XWH2210742U.S. Department of Health & Human Services | NIH | Division of Loan Repayment (DLR) 2-T32-CA-15299-15U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01-CA262619U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01-CA276350U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01-CA279698,
6 · The paper itselfAbstract
SETD2 is a critical tumor suppressor in lung cancer that catalyzes histone H3 lysine 36 (H3K36) trimethylation. Oncogenic histone H3 alleles, including H3
Indexed as
Histone-Lysine N-MethyltransferaseHistonesImmunologic SurveillanceLung NeoplasmsAnimalsCell Line, TumorEnhancer of Zeste Homolog 2 ProteinGene Expression Regulation, NeoplasticHumansLysineMethylationMiceProto-Oncogene Proteins p21(ras)Repressor ProteinsRNA, Double-StrandedEnhancer of Zeste Homolog 2 ProteinEzh2 protein, mouseHistone-Lysine N-MethyltransferaseHistonesHras protein, mouseLysineProto-Oncogene Proteins p21(ras)Repressor ProteinsRNA, Double-StrandedSETD2 protein, humanSETD2 protein, mouse
Identifiers
PMID42875424
PMCPMC13669384
What OpenQuestion holds
Textmetadata
Read underepoch 390